Emily Ricq

Emily Ricq has a diverse work experience in the field of neurodegenerative diseases and therapeutic research. Emily is currently working at Kisbee Therapeutics as the VP of Discovery Biology, where they focus on developing novel therapeutic agents for neurodegenerative diseases. Prior to this role, they served as the Principal Scientist at Kisbee Therapeutics and as the Co-Founder and Associate Director of Biochemistry, where they translated genetic and biochemical insights into therapies for brain health and repair.

Before joining Kisbee Therapeutics, Emily worked at the Broad Institute of MIT and Harvard as a Postdoctoral Fellow in the Chemical Biology and Therapeutics Science department. In this role, they researched the role of ferroptosis in neurodegenerative disorders and developed strategies to target apolipoprotein E (apoE) for the treatment of brain injury and Alzheimer's disease.

Emily's academic background includes being a Graduate Student at Harvard University/Massachusetts General Hospital, where they focused on synthesizing and characterizing compounds for probing epigenetic processes in neurobiology. Their PhD thesis project involved high-throughput screening and the development of label-free cellular thermal shift assays.

During their undergraduate years at The University of Arizona, Emily served as an Undergraduate Researcher in the neurodevelopment labs, where they synthesized and evaluated novel ceramides.

Additionally, Emily worked as a Science Teacher at Agua Caliente Elementary School, further demonstrating their passion for education and sharing their knowledge.

Emily Ricq attended Chandler High School for an unknown duration of time. After completing high school, they went on to pursue a Bachelor of Science degree in Chemistry at the University of Arizona from 2005 to 2009. Following their undergraduate studies, Emily attended Harvard University where they pursued a Doctor of Philosophy (PhD) in Chemistry and Chemical Biology from 2010 to 2016.